Category - Developments

Developments

Soricimed publishes Phase 1 results of SOR-C13

Closely-held Soricimed Biopharma announced publication in the peer-reviewed journal, Investigational New Drugs, The Journal of New Anticancer Agents of its first-in-human Phase 1 study of SOR-C13, a TRPV6 calcium...

February 21, 2017

Developments

Arch advances 510(k) filing for AC5 hemostat

Arch Therapeutics (OTCQB:ARTH) announced that the 510(k) filing for external use of the AC5 Topical Hemostatic device would be advanced to mid-2017 from the previously announced target of late 2017. “Our...

February 17, 2017

Developments

Montreal Heart Institute implements Stereotaxis systems

Stereotaxis (NASDAQ:STXS) announced that the Montreal Heart Institute (MHI) is now performing ablation procedures using its newly installed Niobe ES and the Vdrive robotic systems. MHI is the first hospital in...

February 16, 2017

Developments

Benefits of Titan’s Probuphine featured in DDBN

Drug Deliver Business News has carried an article about Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant, the first marketed product to provide maintenance treatment for opioid addiction continuously for...

February 14, 2017

Developments

Microbix posts 84% jump in Q1 revenue

Microbix Biosystems (TSX:MBX) reported that revenue rose 84% to almost $2-million for the first quarter ended Dec. 31, 2016, from $1.1-million a year earlier. Strong growth in Asian markets and increased sales to the...

February 14, 2017

Developments

IntelGenx, Tetra in development term sheet

IntelGenx (TSX-V:IGX; OTCQX:IGXT) and Tetra Bio-Pharma (CSE:TBP; OTC: GRPOF) announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol. Under the...

February 9, 2017

Developments

YouScript study shows reduced ER visits and readmissions

YouScript, a clinical decision support tool designed to assist in medication therapy management, has been shown to reduce hospital readmissions by 52% and ER visits by 42% in patients over 50 taking multiple medications...

February 7, 2017

Developments

BioTime acquires rights to retinal disease assets

BioTime (NYSE MKT:BTX) has acquired global rights to ophthalmology-related intellectual property assets from the University of Pittsburgh’s Medical Center, via the school’s Innovation Institute. The technology was...

February 6, 2017

Developments

Avivagen undertakes human health proof of concept

Avivagen (TSX-V:VIV), with the help of the National Research Council of Canada (NRC), will undertake a project to establish proof of concept for a first human health application of its OxC-beta technology. The project...

February 3, 2017

Developments

Mass. Life Sciences launches ramp-up program

The Massachusetts Life Sciences Center (MLSC) has launched the Massachusetts Ramp-Up Program (MassRamp), a new program that will provide grant funding to promising early-stage life sciences companies. The program will...

January 31, 2017

Category - Developments

Subscribe